The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...
The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback